WallStreetZenWallStreetZen

NASDAQ: ALLO
Allogene Therapeutics Inc Stock Ownership - Who owns Allogene Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Allogene Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Geoffrey M. ParkerCFO2026-10-2136,342$1.34
$48.70kSell
Earl Martin DouglasCLO;SVP2026-08-2129,697$2.12
$62.96kSell
Annie YoshiyamaSVP Finance2026-04-219,586$2.31
$22.14kSell
Benjamin Machinas BeneskiSVP Chief Technical Officer2026-03-312,867$2.50
$7.17kSell
Benjamin Machinas BeneskiSVP Chief Technical Officer2026-03-164,835$2.47
$11.94kSell
David D. ChangPresident and CEO2026-03-1647,763$2.47
$117.97kSell
Benjamin Machinas BeneskiSVP Chief Technical Officer2026-03-027,132$2.60
$18.54kSell
Earl Martin DouglasSVP General Counsel2026-02-0222,900$1.76
$40.30kSell
Benjamin Machinas BeneskiSVP Chief Technical Officer2026-02-027,549$1.73
$13.06kSell
David D. ChangPresident and CEO2026-02-0295,269$1.80
$171.48kSell

1 of 2

ALLO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALLO insiders and whales buy or sell their stock.

ALLO Shareholders

What type of owners hold Allogene Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Pfizer Inc6.38%22,032,040$22.91MInsider
Tpg GP A LLC5.42%18,716,306$19.46MInsider
Tpg Group Holdings Sbs Advisors Inc5.42%18,716,306$19.46MInsider
David D. Chang1.84%6,351,707$6.61MInsider
Eric Thomas Schmidt0.92%3,167,629$3.29MInsider
Arie Belldegrun0.80%2,776,683$2.89MInsider
Geoffrey M. Parker0.30%1,045,877$1.09MInsider
Alison Moore0.19%672,731$699.64kInsider
Zachary Roberts0.17%581,166$604.41kInsider
Veer Bhavnagri0.16%556,049$578.29kInsider

1 of 3

ALLO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALLO0.09%22.48%Net SellingNet Selling
LYEL0.01%99.99%Net BuyingNet Buying
SRZN0.04%99.96%Net BuyingNet Buying
IRD0.02%99.98%Net SellingNet Buying
AVTX0.09%99.91%Net SellingNet Selling
View Top Biotech Stocks

Allogene Therapeutics Stock Ownership FAQ

Who owns Allogene Therapeutics?

Allogene Therapeutics (NASDAQ: ALLO) is owned by 0.09% institutional shareholders, 22.48% Allogene Therapeutics insiders, and 77.43% retail investors. Pfizer Inc is the largest individual Allogene Therapeutics shareholder, owning 22.03M shares representing 6.38% of the company. Pfizer Inc's Allogene Therapeutics shares are currently valued at $22.91M.

If you're new to stock investing, here's how to buy Allogene Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.